Ferroptosis driven by nanoparticles for tackling glioblastoma
Open Access
- 14 December 2024
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 611, 217392
Abstract
No abstract availableKeywords
Funding Information
- Foundation for Science and Technology
This publication has 127 references indexed in Scilit:
- Ferroptosis crosstalk in anti-tumor immunotherapy: molecular mechanisms, tumor microenvironment, application prospectsApoptosis, 2024
- The Mutual Regulatory Role of Ferroptosis and Immunotherapy in Anti-tumor TherapyApoptosis, 2024
- FSP1-mediated ferroptosis in cancer: from mechanisms to therapeutic applicationsApoptosis, 2024
- Molecular mechanisms of ferroptosis and relevance to inflammationInflammation Research, 2022
- Ferroptosis: From regulation of lipid peroxidation to the treatment of diseasesCell Biology and Toxicology, 2022
- System Xc−: a key regulatory target of ferroptosis in cancerInvestigational New Drugs, 2021
- Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapyProtein & Cell, 2020
- Cystine‐glutamate antiporter xCT as a therapeutic target for cancerCell Biochemistry and Function, 2020
- Progesterone at high doses reduces the growth of U87 and A172 glioblastoma cells: Proteomic changes regarding metabolism and immunityCancer Medicine, 2020
- T98G: An anchorage‐independent human tumor cell line that exhibits stationary phase G1 arrest in vitroJournal of Cellular Physiology, 1979